These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 10575319

  • 1. Expression of p53 and glutathione S-transferase-pi relates to clinical drug resistance in non-small cell lung cancer.
    Nakanishi Y, Kawasaki M, Bai F, Takayama K, Pei XH, Takano K, Inoue K, Osaki S, Hara N, Kiyohara C.
    Oncology; 1999 Nov; 57(4):318-23. PubMed ID: 10575319
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.
    Miyatake K, Gemba K, Ueoka H, Nishii K, Kiura K, Tabata M, Shibayama T, Takigawa N, Kawaraya M, Tanimoto M.
    Anticancer Res; 2003 Nov; 23(3C):2829-36. PubMed ID: 12926120
    [Abstract] [Full Text] [Related]

  • 3. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi.
    Mathieu A, Remmelink M, D'Haene N, Penant S, Gaussin JF, Van Ginckel R, Darro F, Kiss R, Salmon I.
    Cancer; 2004 Oct 15; 101(8):1908-18. PubMed ID: 15386340
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma.
    Bai F, Nakanishi Y, Kawasaki M, Takayama K, Yatsunami J, Pei XH, Tsuruta N, Wakamatsu K, Hara N.
    Cancer; 1996 Aug 01; 78(3):416-21. PubMed ID: 8697385
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemical expression of glutathione transferase-pi in untreated primary non-small-cell lung cancer.
    Arai T, Yasuda Y, Takaya T, Hayakawa K, Toshima S, Shibuya C, Kashiki Y, Yoshimi N, Shibayama M.
    Cancer Detect Prev; 2000 Aug 01; 24(3):252-7. PubMed ID: 10975287
    [Abstract] [Full Text] [Related]

  • 6. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers.
    Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akita H, Nishimura M.
    Cancer Sci; 2003 Apr 01; 94(4):394-9. PubMed ID: 12824911
    [Abstract] [Full Text] [Related]

  • 7. P53 immunostaining predicts chemosensitivity in non-small cell lung cancer: A preliminary report.
    Kawasaki M, Nakanishi Y, Yatsunami J, Takayama K, Ochiai S, Xinhai P, Kuwano K, Hara N.
    Cancer J Sci Am; 1996 Apr 01; 2(4):217-20. PubMed ID: 9166535
    [Abstract] [Full Text] [Related]

  • 8. The expression of GST isoenzymes and p53 in non-small cell lung cancer.
    Oguztüzun S, Aydin M, Demirag F, Yazici U, Ozhavzali M, Kiliç M, Işcan M.
    Folia Histochem Cytobiol; 2010 Jan 01; 48(1):122-7. PubMed ID: 20529827
    [Abstract] [Full Text] [Related]

  • 9. Serum glutathione S-transferase-pi level as a tumor marker for non-small cell lung cancer. Potential predictive value in chemotherapeutic response.
    Hida T, Kuwabara M, Ariyoshi Y, Takahashi T, Sugiura T, Hosoda K, Niitsu Y, Ueda R.
    Cancer; 1994 Mar 01; 73(5):1377-82. PubMed ID: 8111704
    [Abstract] [Full Text] [Related]

  • 10. Glutathione-S transferase-pi expression in non small cell lung cancer in the assessment of response to chemotherapy.
    Unsal M, Akpolat I, Kandemir B.
    Saudi Med J; 2003 May 01; 24(5):493-8. PubMed ID: 12847624
    [Abstract] [Full Text] [Related]

  • 11. [Multidrug resistance and its relationship with neuroendocrine differentiation in non-small cell lung carcinoma].
    Yu SP, Xiong YY, Tian SF.
    Zhonghua Jie He He Hu Xi Za Zhi; 2003 Mar 01; 26(3):165-8. PubMed ID: 12816683
    [Abstract] [Full Text] [Related]

  • 12. Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy.
    Hsu CH, Chen CL, Hong RL, Chen KL, Lin JF, Cheng AL.
    Oncology; 2002 Mar 01; 62(4):305-12. PubMed ID: 12138237
    [Abstract] [Full Text] [Related]

  • 13. Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer.
    Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C, Hara N.
    Eur J Cancer; 1998 Aug 01; 34(9):1352-7. PubMed ID: 9849416
    [Abstract] [Full Text] [Related]

  • 14. Expression of drug resistance gene products during progression of lung carcinomas.
    Mattern J, Koomägi R, Volm M.
    Oncol Rep; 2002 Aug 01; 9(6):1181-4. PubMed ID: 12375015
    [Abstract] [Full Text] [Related]

  • 15. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Gregorc V, Ludovini V, Pistola L, Darwish S, Floriani I, Bellezza G, Sidoni A, Cavaliere A, Scheibel M, De Angelis V, Bucciarelli E, Tonato M.
    Lung Cancer; 2003 Jan 01; 39(1):41-8. PubMed ID: 12499093
    [Abstract] [Full Text] [Related]

  • 16. [Correlation between an enzyme (glutathione S-transferase-pi) and effects of chemotherapy (cisplatin + etoposide)].
    Arai T, Yasuda Y, Ito Y, Hayakawa K, Takaya T, Toshima S, Shibuya C, Nawada M, Shibayama M, Yoshimi N, Ito H, Fujiwara H.
    Gan To Kagaku Ryoho; 1996 Jun 01; 23(7):881-5. PubMed ID: 8678536
    [Abstract] [Full Text] [Related]

  • 17. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY, Liang XM, Lin SX, Luo RZ, Hou JH, Zhang L.
    Ai Zheng; 2004 Jul 01; 23(7):845-50. PubMed ID: 15248926
    [Abstract] [Full Text] [Related]

  • 18. [The relationship between drug sensitivity and expression of drug resistance gene mutations in non-small cell lung cancer].
    Han B, Liao M, Su J, Feng J, Wang E, Dong Q.
    Zhonghua Jie He He Hu Xi Za Zhi; 2002 Dec 01; 25(12):727-31. PubMed ID: 12622891
    [Abstract] [Full Text] [Related]

  • 19. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC, Lin PL, Wang YC, He TY, Lee MC, Yeh SD, Chen CY, Lee H.
    Oncotarget; 2015 Dec 08; 6(39):41692-705. PubMed ID: 26497680
    [Abstract] [Full Text] [Related]

  • 20. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
    Cheng C, Wu YL, Gu LJ, Chen G, Weng YM, Feng WN, Zhong WZ.
    Ai Zheng; 2005 Jul 08; 24(7):846-9. PubMed ID: 16004813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.